Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Sidney Kimmel Comprehensive Cancer Center National Cancer Institute (NCI) |
---|---|
Information provided by: | National Cancer Institute (NCI) |
ClinicalTrials.gov Identifier: | NCT00660348 |
RATIONALE: Giving medications in different ways may change their effectiveness in controlling pain. It is not yet known whether intrathecal therapy is more effective than standard therapy in controlling pain in patients with pancreatic cancer.
PURPOSE: This randomized clinical trial is studying standard pain control to see how well it works compared with intrathecal therapy in controlling pain in patients with locally advanced, unresectable, or metastatic pancreatic cancer.
Condition | Intervention |
---|---|
Pain Pancreatic Cancer |
Drug: bupivacaine hydrochloride Drug: clonidine Drug: morphine sulfate Procedure: assessment of therapy complications Procedure: quality-of-life assessment |
Study Type: | Interventional |
Study Design: | Supportive Care, Randomized, Open Label |
Official Title: | A Randomized Study of Optimal Pain Management: Standard Pain Control Versus Early Intervention With Intrathecal Therapy in Patients With Advanced Pancreatic Cancer |
Estimated Enrollment: | 80 |
Study Start Date: | March 2008 |
Estimated Primary Completion Date: | December 2010 (Final data collection date for primary outcome measure) |
OBJECTIVES:
Primary
Secondary
OUTLINE: Patients are stratified according to Karnofsky performance status (60-80% vs > 80%). Patients are randomized to 1 of 2 treatment arms.
After completion of study treatment, patients are followed for 1 year.
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
Inclusion criteria:
Histologically confirmed adenocarcinoma of the pancreas
Exclusion criteria:
PATIENT CHARACTERISTICS:
Inclusion criteria:
Exclusion criteria:
Uncontrolled medical conditions that could potentially increase the risk of toxicities or complications of this therapy, including any of the following:
PRIOR CONCURRENT THERAPY:
United States, Maryland | |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting |
Baltimore, Maryland, United States, 21231-2410 | |
Contact: Clinical Trials Office - Sidney Kimmel Comprehensive Cancer Ce 410-955-8804 jhcccro@jhmi.edu |
Principal Investigator: | Michael Erdek, MD | Sidney Kimmel Comprehensive Cancer Center |
Study ID Numbers: | CDR0000593173, JHOC-J0724, JHOC_NA_00009208 |
Study First Received: | April 16, 2008 |
Last Updated: | July 7, 2009 |
ClinicalTrials.gov Identifier: | NCT00660348 History of Changes |
Health Authority: | Unspecified |
recurrent pancreatic cancer stage III pancreatic cancer stage IV pancreatic cancer |
adenocarcinoma of the pancreas pain stage II pancreatic cancer |
Morphine Digestive System Neoplasms Pancreatic Neoplasms Clonidine Central Nervous System Depressants Anesthetics Endocrine System Diseases Narcotics Pain Pancrelipase Anesthetics, Local |
Recurrence Digestive System Diseases Gastrointestinal Neoplasms Pancreatic Diseases Bupivacaine Analgesics Peripheral Nervous System Agents Endocrinopathy Adenocarcinoma Analgesics, Opioid Endocrine Gland Neoplasms |
Morphine Digestive System Neoplasms Pancreatic Neoplasms Physiological Effects of Drugs Endocrine System Diseases Anesthetics Central Nervous System Depressants Narcotics Pharmacologic Actions Anesthetics, Local Neoplasms |
Neoplasms by Site Digestive System Diseases Sensory System Agents Therapeutic Uses Pancreatic Diseases Bupivacaine Analgesics Peripheral Nervous System Agents Central Nervous System Agents Analgesics, Opioid Endocrine Gland Neoplasms |